Lonza to Establish Large-Scale Commercial Pharmaceutical Filling and Finishing Facility in Stein (CH)

  • Lonza will construct a new large-scale commercial pharmaceutical filling and finishing facility to support customers throughout the product lifecycle
  • Lonza will invest approximately CHF 500 million in the facility, fulfilling its strategic commitment to establish a fill and finish business offering that complements its full value chain

Basel, Switzerland, July 1, 2022 – Lonza, a global development and manufacturing partner to the pharmaceutical, biotechnology and nutrition industries, today announced plans to build a large-scale commercial pharmaceutical filling and finishing facility in Stein, CH.

The investment will enable the company to provide its customers with a comprehensive, integrated end-to-end solution that includes commercial drug manufacturing for large-scale market supply. The new facility will be delivered with an investment of approximately 500 million francs and is expected to be completed in 2026.

Pierre-Alain Ruffieux, CEO of Lonza, said: “This strategic investment complements our pharmaceutical product offering and reinforces our position as a CDMO leader with an unparalleled range of offerings across scales and technologies. Combined with our strong drug substance manufacturing footprint, the new facility will enable us to provide customers with an end-to-end integrated offering throughout the lifecycle of their products.

Jean-Christophe Hyvert, President, Biologics and Cell & Gene, Lonza, added: “As Lonza continues to develop its end-to-end offering in pharmaceutical manufacturing, we are providing our customers with integrated offerings that will increase speed to market, flexibility and simplicity, in line with our strategy. Leveraging our experience and expertise in solving pharmaceutical development, formulation and manufacturing challenges, this new facility will allow us to capture additional market share and meet continued customer demand for manufacturing of commercial pharmaceuticals.

Since establishing pharmaceutical development and manufacturing services in 2016, Lonza has expanded its clinical pharmaceutical offerings by Basel, Stein and Visp (CH), and Canton (CN). This significant new investment in commercial drug manufacturing complements Lonza’s strategic commitment to offer an integrated end-to-end service.

The new flexible facility will be built in Stein (CH) on the same campus as Lonza’s current clinical pharmaceuticals facility, allowing the company to leverage existing infrastructure, capabilities and talent.

The facility will adopt the latest developments in sustainable construction, taking a modern approach to carbon reduction and responsible energy use, including the installation of a photovoltaic roof.

About Lonza
Lonza is a preferred global partner for the pharmaceutical, biotechnology and nutrition markets. We work to enable a healthier world by helping our customers deliver new and innovative medicines that help treat a wide range of diseases. We achieve this by combining technological insight with world-class manufacturing, scientific expertise and process excellence. Our unparalleled range of offerings enable our customers to commercialize their healthcare discoveries and innovations.

Founded in 1897 in the Swiss Alps, Lonza today operates on five continents. With approximately 16,000 employees (full-time equivalent), we are made up of high-performing teams and individual talents who make a meaningful difference to our own business, as well as to the communities in which we operate. The company achieved a turnover of 5.4 billion francs with a CORE EBITDA of 1.7 billion francs for the year 2021. To find out more, go to www.lonza.com

Follow @Lonza on LinkedIn
Follow @LonzaGroup on Twitter

Additional Information and Disclaimer
Lonza Group SA is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the ongoing registration requirements of the SGX-ST, but remains subject to Rules 217 and 751 of the SGX-ST Registration Handbook.
Certain matters discussed in this press release may constitute forward-looking statements. These statements are based on Lonza Group Ltd’s current expectations and estimates, although Lonza Group Ltd cannot guarantee that such expectations and estimates will be realized. Investors are cautioned that all forward-looking statements involve risks and uncertainties and are qualified in their entirety. Actual results may differ materially in the future from the forward-looking statements included in this press release due to a variety of factors. Further, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this press release.

Link to privacy policy

To delete all data immediately


Comments are closed.